Bedfont Scientific makes FDA 510(k) submission for clearance of ToxCO monitor

Bedfont Scientific Ltd. has made a 510(k) submission for US FDA clearance of their ToxCO® monitor used by emergency services to mass screen for carbon monoxide (CO) poisoning.

Bedfont, based in the UK, specialists in the design and manufacture of breath analysis medical products, has made an FDA 510(k) submission for clearance to sell one of its breath analyzers, the ToxCO®.

Established in 1976, the second-generation family company already has one device on the market in America, their Micro+™ Smokerlyzer® CO monitor to help people quit smoking. Using a similar technology, the ToxCO® is designed for emergency services to mass screen for cases of CO poisoning, providing a quicker method than the traditional blood test. A breath sample can be taken from a patient via mouthpiece, or in instances where the patient is unconscious, by face mask. By being able to mass screen patients on-site, it can rule out unnecessary hospital admissions and save valuable time, furthermore, the ToxCO® has ambient monitoring which begins from switch-on, alerting emergency services to high levels of atmospheric CO at the scene of the incident, helping to safeguard them and be prepared.

Known as the silent killer, CO is a colorless, odorless, highly poisonous gas that is produced when fuels are burned incompletely. Everybody is exposed to CO in everyday life; from boilers, open fires, cars, generators and even burning your toast. CO poisoning is the most common type of fatal poisoning in many countries. According to the CDC, “during 1999–2010, a total of 5,149 deaths from unintentional carbon monoxide poisoning occurred in the United States, an average of 430 deaths per year”. Prolonged exposure can lead to severe health consequences, and if exposed for too long, death. An exposure to 12,800ppm of carbon monoxide can kill you within 1-3 minutes.

Jason Smith, Managing Director at Bedfont, explains:

We are working hard to help raise awareness of breath analysis in the USA and how the ToxCO® has the potential to save so many lives. We are fully committed to working closely everyone involved to have swift and successful FDA clearance for this product.

Daniel Sibis, Vice President at coVita LLC, Bedfont’s USA distributor, comments:

The ToxCO® will revolutionise how emergency services approach carbon monoxide poisoning. Compared to blood samples, breath analysis with the ToxCO® is quick, easy and completely non-invasive. This means no more needles and with values shown instantly onscreen, the ToxCO® will save more lives.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Routine blood test may flag hidden osteoporosis risk, study finds